Maze Therapeutics (MAZE) News Today $27.43 -1.33 (-4.62%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MAZE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Weiss Ratings Reaffirms "Sell (D)" Rating for Maze Therapeutics (NASDAQ:MAZE)October 10 at 8:11 AM | marketbeat.comMapLight’s $251m IPO sees schizophrenia drug developers on topOctober 8 at 6:33 PM | msn.comMaze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High - What's Next?October 6, 2025 | marketbeat.comMaze Therapeutics Appoints Hervé Hoppenot as ChairmanOctober 6, 2025 | tipranks.comMaze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of DirectorsOctober 6, 2025 | globenewswire.comMaze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price SurgeOctober 4, 2025 | finance.yahoo.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Maze Therapeutics (NASDAQ:MAZE) StockOctober 1, 2025 | americanbankingnews.comGoldman Sachs Group Inc. Makes New $145,000 Investment in Maze Therapeutics, Inc. $MAZESeptember 30, 2025 | marketbeat.comJP Morgan Maintains Maze Therapeutics (MAZE) Overweight RecommendationSeptember 29, 2025 | msn.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.2% - Should You Sell?September 29, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00 at JPMorgan Chase & Co.September 29, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.4% - Still a Buy?September 25, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Reaches New 52-Week High - Here's WhySeptember 24, 2025 | marketbeat.comMaze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by AnalystsSeptember 21, 2025 | marketbeat.comMaze Therapeutics, Inc. (MAZE): A Bull Case TheorySeptember 20, 2025 | finance.yahoo.comMaze Therapeutics, Inc. (MAZE): A Bull Case TheorySeptember 19, 2025 | msn.comMaze Therapeutics, Inc. (MAZE): A Bull Case Theory September 19, 2025 | insidermonkey.comMaze Therapeutics' (MAZE) Buy Rating Reaffirmed at HC WainwrightSeptember 19, 2025 | marketbeat.comBiotech Breakouts: 3 Stocks With Massive Upside PotentialBiotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential...September 17, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Director Richard Scheller Sells 20,744 SharesSeptember 17, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Shares Gap Down - Here's WhySeptember 17, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Director Sells $464,043.28 in StockSeptember 17, 2025 | insidertrades.comGuggenheim Forecasts Strong Price Appreciation for Maze Therapeutics (NASDAQ:MAZE) StockSeptember 16, 2025 | marketbeat.comMaze Therapeutics price target raised to $34 from $19 at GuggenheimSeptember 15, 2025 | msn.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, HC Wainwright Analyst SaysSeptember 14, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Given New $37.00 Price Target at BTIG ResearchSeptember 14, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Hits New 1-Year High - Should You Buy?September 14, 2025 | marketbeat.comWoodline Partners LP Invests $10.23 Million in Maze Therapeutics, Inc. $MAZESeptember 14, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's What HappenedSeptember 13, 2025 | marketbeat.comMaze Therapeutics price target raised to $50 from $34 at H.C. WainwrightSeptember 12, 2025 | msn.comMaze Therapeutics price target raised to $37 from $30 at BTIGSeptember 12, 2025 | msn.comMaze reports positive results from Phase I trial of PKU and CKD treatmentSeptember 12, 2025 | finance.yahoo.comMaze Therapeutics Advances Clinical Programs Amid Financial StabilitySeptember 11, 2025 | tipranks.comMaze Vaults on Oversubcribed Private PlacementSeptember 11, 2025 | baystreet.caMaze Therapeutics climbs after early-stage trial data for rare disease drugSeptember 11, 2025 | msn.comWhy Maze Therapeutics, Up 55%, Was Shocked By Its Own Test ResultsSeptember 11, 2025 | msn.comMaze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)September 11, 2025 | seekingalpha.comMaze Therapeutics, Inc. (MAZE) Discusses MZE782 Phase 1 Healthy Volunteer Results (Transcript)September 11, 2025 | seekingalpha.comMaze Therapeutics, Inc. (MAZE) Special Call - SlideshowSeptember 11, 2025 | seekingalpha.comMaze Therapeutics (NASDAQ:MAZE) Trading Up 7.5% - Here's What HappenedSeptember 11, 2025 | marketbeat.comMaze Therapeutics Secures $150M in Private PlacementSeptember 11, 2025 | tipranks.comMaze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to ...September 11, 2025 | markets.businessinsider.comMaze Therapeutics Secures $150 Million in Oversubscribed Private Placement to Advance Kidney and Metabolic Disease TherapiesSeptember 11, 2025 | quiverquant.comQMaze Therapeutics Announces Oversubscribed $150.0 Million Private PlacementSeptember 11, 2025 | globenewswire.comMaze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)September 11, 2025 | globenewswire.comOctagon Capital Advisors LP Takes Position in Maze Therapeutics, Inc. $MAZESeptember 11, 2025 | marketbeat.comInvesco Ltd. Acquires Shares of 20,552 Maze Therapeutics, Inc. $MAZESeptember 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes $1.38 Million Position in Maze Therapeutics, Inc. $MAZESeptember 8, 2025 | marketbeat.comARCH Venture Management LLC Purchases Shares of 4,120,053 Maze Therapeutics, Inc. $MAZESeptember 5, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Up 6.8% - Still a Buy?September 4, 2025 | marketbeat.com Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAZE Media Mentions By Week MAZE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MAZE News Sentiment▼0.410.77▲Average Medical News Sentiment MAZE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MAZE Articles This Week▼84▲MAZE Articles Average Week Get the Latest News and Ratings for MAZE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Maze Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Arcellx News Today Kymera Therapeutics News Today Protagonist Therapeutics News Today Jyong Biotech News Today Crinetics Pharmaceuticals News Today Zai Lab News Today Akero Therapeutics News Today Ascentage Pharma Group International News Today Mirum Pharmaceuticals News Today ACADIA Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MAZE) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
